PULMHealthcare · BiotechnologyPULM Stock Forecast: Pulmatrix, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 1 Aug 2026 — in the lower half.
PULM stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Pulmatrix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Pulmatrix, Inc. — and when they’d sell — is the membership.
PULM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PULM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 15 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Apr 2021 | HC Wainwright & Co. | Maintains | Buy | $10 → $5.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PULM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Pulmatrix, Inc. (PULM) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.2×
- Price / sales
- —
- Price / book
- 2.4×
- EV / EBITDA
- −0.8×
Cheaper than 83% of US stocks
Cheaper than 40% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −84.3%
- Return on assets
- −46.0%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PULM vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PULM appears on the weeks it earns a place.
Frequently asked questions about PULM stock
Is PULM stock a buy right now?
Of the 1 analysts covering Pulmatrix, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmatrix, Inc. 39 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PULM?
As at 1 Aug 2026, Pulmatrix, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
What is the PULM stock forecast for 2030?
No analyst covering Pulmatrix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PULM are extrapolating price history, which says nothing about the business.
How has PULM stock performed over the past year?
Pulmatrix, Inc. returned -67.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pulmatrix, Inc. do?
Pulmatrix Inc. is a biotechnology company focused on the discovery and development of innovative inhaled therapies to address significant unmet needs in respiratory diseases.
About Pulmatrix, Inc.
Pulmatrix Inc. is a biotechnology company focused on the discovery and development of innovative inhaled therapies to address significant unmet needs in respiratory diseases. The company's primary function is to leverage its proprietary iSPERSE inhaled dry powder technology to create therapies that improve treatment delivery and efficacy. Pulmatrix aims to transform the treatment landscape for diseases such as chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fungal infections. By targeting the respiratory system directly, Pulmatrix's products hold the potential for faster and more efficient drug delivery, reducing systemic side effects. Headquartered in Massachusetts, Pulmatrix operates within the pharmaceutical and healthcare sectors, collaborating with research institutions and companies to advance its clinical programs. Its market significance is underscored by its commitment to enhancing patient care through innovative treatments specifically designed for pulmonary conditions.
CEO Mr. Peter Ludlum CMA, MBA · 2 employees · United States · https://www.pulmatrix.com